Bankruptcy Court Gives Green Light To Akorn Sale
Akorn “Working To Finalize Deal” With Existing Lenders
Executive Summary
Just three years after Fresenius Kabi agreed a $4.75bn takeover of the US injectables specialist, Akorn has obtained approval from a US bankruptcy court for its sale to the company’s existing lenders, having filed for Chapter 11 bankruptcy earlier this year.
You may also be interested in...
Akorn Offloads Consumer Health For $230m
Akorn has announced a $230m all-cash deal to divest its consumer healthcare business to Prestige Consumer Healthcare. The transaction will allow Akorn – which recently went through bankruptcy proceedings – to invest in optimizing its prescription business.
Akorn Reviews Future Of Consumer Health Portfolio
US injectables specialist Akorn has begun to review strategic alternatives for its consumer health business, as the company looks at divesting some of its brands to increase financial flexibility and focus on its prescription generic and branded portfolio.
FDA Set To Make Key Decision On Restasis Generics
Despite the door being opened for generic competition to Restasis more than a year, no FDA approvals for ANDAs referencing the eye-disease drug have been forthcoming. However, that could change before the year is out.